Total Payments
$13,240
2024 Payments
$2,434
Companies
30
Transactions
926
Medicare Patients
1,028
Medicare Billing
$195,392
Payment Breakdown by Category
Food & Beverage$13,015 (98.3%)
Education$225.10 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,015 | 916 | 98.3% |
| Education | $225.10 | 10 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $3,446 | 254 | $0 (2024) |
| ABBVIE INC. | $2,317 | 179 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,420 | 111 | $0 (2024) |
| PFIZER INC. | $1,418 | 122 | $0 (2024) |
| Janssen Biotech, Inc. | $933.42 | 41 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $683.37 | 32 | $0 (2024) |
| UCB, Inc. | $543.29 | 32 | $0 (2024) |
| Lilly USA, LLC | $410.34 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $359.33 | 18 | $0 (2024) |
| Celgene Corporation | $307.99 | 36 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,434 | 167 | Amgen Inc. ($439.36) |
| 2023 | $1,559 | 120 | ABBVIE INC. ($495.64) |
| 2022 | $2,297 | 146 | ABBVIE INC. ($562.00) |
| 2021 | $1,837 | 126 | Amgen Inc. ($630.74) |
| 2020 | $1,693 | 106 | Amgen Inc. ($683.61) |
| 2019 | $1,123 | 88 | Amgen Inc. ($299.25) |
| 2018 | $1,124 | 90 | Amgen Inc. ($285.58) |
| 2017 | $1,174 | 83 | Novartis Pharmaceuticals Corporation ($270.94) |
All Payment Transactions
926 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $9.32 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $11.34 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/02/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $10.01 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.26 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Bone Health | ||||||
| 11/20/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: Immunology | ||||||
| 11/12/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $6.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.70 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $7.89 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/31/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $4.42 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.22 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $5.41 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 233 | 2,141 | $110,806 | $55,026 |
| 2022 | 8 | 258 | 2,025 | $92,957 | $50,532 |
| 2021 | 9 | 276 | 2,015 | $82,208 | $52,077 |
| 2020 | 9 | 261 | 1,569 | $68,763 | $37,756 |
Total Patients
1,028
Total Services
7,750
Medicare Billing
$195,392
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 1,800 | $68,400 | $32,054 | 46.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 188 | $25,380 | $15,860 | 62.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $10,192 | $5,275 | 51.8% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 16 | 23 | $4,172 | $1,135 | 27.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 49 | $1,862 | $509.47 | 27.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 15 | 32 | $800.00 | $192.86 | 24.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 18 | 1,680 | $47,640 | $26,908 | 56.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 176 | $23,760 | $13,630 | 57.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $10,608 | $5,484 | 51.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 25 | $4,550 | $2,286 | 50.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 14 | $1,260 | $841.31 | 66.8% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 12 | 15 | $2,980 | $768.72 | 25.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 43 | $1,634 | $440.93 | 27.0% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 12 | 21 | $525.00 | $172.56 | 32.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 16 | 1,620 | $32,400 | $24,805 | 76.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 189 | $25,515 | $15,812 | 62.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $9,568 | $5,245 | 54.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 21 | $3,822 | $2,552 | 66.8% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 20 | 32 | $6,109 | $1,548 | 25.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 27 | $2,430 | $1,525 | 62.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 17 | 28 | $1,064 | $295.93 | 27.8% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 14 | 18 | $450.00 | $152.86 | 34.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 16 | 34 | $850.00 | $142.51 | 16.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 14 | 1,200 | $24,000 | $17,943 | 74.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 100 | 175 | $23,625 | $11,108 | 47.0% |
About Dr. Anna Gramling, MD
Dr. Anna Gramling, MD is a Rheumatology healthcare provider based in Plainfield, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508033408.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Gramling, MD has received a total of $13,240 in payments from pharmaceutical and medical device companies, with $2,434 received in 2024. These payments were reported across 926 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($13,015).
As a Medicare-enrolled provider, Gramling has provided services to 1,028 Medicare beneficiaries, totaling 7,750 services with total Medicare billing of $195,392. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Plainfield, IN
- Active Since 05/11/2008
- Last Updated 12/15/2025
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1508033408
Products in Payments
- Enbrel (Biological) $2,142
- RINVOQ (Biological) $1,169
- COSENTYX (Biological) $1,159
- XELJANZ (Drug) $1,152
- ORENCIA (Biological) $683.37
- EVENITY (Biological) $643.75
- TREMFYA (Drug) $521.52
- Cimzia (Drug) $504.94
- SKYRIZI (Biological) $430.75
- TALTZ (Drug) $362.87
- Humira (Biological) $304.93
- KRYSTEXXA (Biological) $251.95
- Otezla (Drug) $227.62
- REMICADE (Biological) $225.83
- KEVZARA (Biological) $220.98
- INFLECTRA (Biological) $211.58
- BENLYSTA (Biological) $193.99
- SAPHNELO (Biological) $192.97
- COSENTYX (Drug) $165.66
- Prolia (Biological) $154.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.